IL15 and myelodysplastic syndrome: The only clinical results from this class of drugs come from the dose-finding study of GTB-3550, a CD16/IL-15/CD33 TriKE tested in R/R AML and R/R high-risk MDS, presented at the 2020 ASH meeting.